Critical Care
Tools
Share this article

Email updates

Keep up to date with the latest news and articles from Critical Care and BioMed Central.

This article is part of the supplement: 24th International Symposium on Intensive Care and Emergency Medicine

Poster presentation

Hemodynamic support with the Impella acute 100 in patients with cardiogenic chock, or high-risk coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)

J Dens1, B Meyens1, J Maessen2, V van Ommen2 and E Grübe3

Author Affiliations

1 UZ Gasthuisberg (KUL), Leuven, Belgium

2 UH, Maastricht, The Netherlands

3 UH, Siegburg, Germany

For all author emails, please log on.

Critical Care 2004, 8(Suppl 1):P97 doi:10.1186/cc2564


The electronic version of this article is the complete one and can be found online at:


Published:15 March 2004

©

Background

The Impella device is a 13 F microaxial blood pump allowing femoral vascular access. It provides nonpulsatile blood flow of up to 2.4 l/min.

Aim

To assess the safety, feasibility and efficacy of the Impella device in patients with cardiogenic shock or patients undergoing high-risk surgery or PCI.

Study

A triple-centre, prospective, nonrandomised two-arm study.

Methods

The patient population was: Arm 1, cardiogenic shock patients with low cardiac output defined as a cardiac index < 2.0 l/min/m2 and pulmonary capillary wedge pressure (PCW) > 18 mmHg, or patients with PCW > 18 mmHg and a systolic blood pressure (BP) < 90 mmHg or in need of inotropes to keep systolic BP > 90 mmHg; and Arm 2: high-risk CABG or high-risk PCI following the Euroscore criteria. Sample size: 20/45 patients are included. Hemodynamics included the assessment of cardiac output (CO), PCW, arteria pulmonalis (AP), arterial BP and intracardiac pump parameters. Biochemistry included free hemoglobin at baseline, each hour during the pump run and 6 hours after removal of the pump.

Results

The results of the first 20 patients are presented in Tables 1 and 2.

Table 1.

Table 2.

Conclusions

These preliminary data indicate the feasibility of the Impella pump for patients in cardiogenic shock, high-risk CABG and PCI. More data will be available in March 2004.